90. Retinitis pigmentosa Clinical trials / Disease details
Clinical trials : 130 / Drugs : 180 - (DrugBank : 41) / Drug target genes : 49 - Drug target pathways : 109
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02661711 (ClinicalTrials.gov) | March 2016 | 13/1/2016 | Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study | Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP) | Macular Oedema;Retinitis Pigmentosa | Drug: Aflibercept | Moorfields Eye Hospital NHS Foundation Trust | Bayer | Active, not recruiting | 16 Years | N/A | Both | 30 | Phase 2 | United Kingdom |
| 2 | EUCTR2015-003723-65-GB (EUCTR) | 12/01/2016 | 06/01/2016 | Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eye | Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOUR | Retinitis Pigmentosa associated Cystoid Macular Oedema MedDRA version: 18.1;Level: PT;Classification code 10038914;Term: Retinitis pigmentosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Eylea Product Name: Eylea Product Code: n/a INN or Proposed INN: Aflibercept | Moorfields Eye Hospital | NULL | Not Recruiting | Female: yes Male: yes | 30 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom |